Cargando…

A Systematic Literature Review of the Epidemiology, Health-Related Quality of Life Impact, and Economic Burden of Immunoglobulin A Nephropathy

Introduction: This systematic literature review analyzed published evidence on IgA nephropathy (IgAN), focusing on US epidemiology, health-related quality of life (HRQoL), and economic burden of illness. Methods: Using Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, Em...

Descripción completa

Detalles Bibliográficos
Autores principales: Kwon, Christina Soeun, Daniele, Patrick, Forsythe, Anna, Ngai, Christopher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Columbia Data Analytics, LLC 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8410133/
https://www.ncbi.nlm.nih.gov/pubmed/34692885
http://dx.doi.org/10.36469/001c.26129
_version_ 1783747099774418944
author Kwon, Christina Soeun
Daniele, Patrick
Forsythe, Anna
Ngai, Christopher
author_facet Kwon, Christina Soeun
Daniele, Patrick
Forsythe, Anna
Ngai, Christopher
author_sort Kwon, Christina Soeun
collection PubMed
description Introduction: This systematic literature review analyzed published evidence on IgA nephropathy (IgAN), focusing on US epidemiology, health-related quality of life (HRQoL), and economic burden of illness. Methods: Using Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, Embase®, MEDLINE®, Cochrane, and Econlit (January 2010 to June 2020) were searched, along with relevant congresses (2017-2020). Results: Of 123 epidemiologic studies selected for data extraction, 24 reported IgAN diagnosis rates ranging from 6.3% to 29.7% among adult and pediatric patients undergoing renal biopsy, with all reported US rates <15%. No US studies reported IgAN prevalence. A meta-analysis of US studies calculated an annual incidence of 1.29/100 000 people, translating to an annual US incidence of 4236 adults and children. Relative to Europe, the United States had more patients diagnosed with IgAN in later chronic kidney disease stages. US rates of transition to end-stage renal disease (ESRD) ranged from 12.5% to 23% during 3-3.9 years of observation, rising to 53% during 19 years of observation. Across 8 studies reporting HRQoL, pain and fatigue were the most reported symptoms, and patients consistently ranked kidney function and mortality as the most important treatment outcomes. Patients with glomerulopathy reported worse mental health than healthy controls or hemodialysis patients; proteinuria was significantly associated with poorer HRQoL and depression. Conclusion: While economic evidence in IgAN remains sparse, management of ESRD is a major cost driver. IgAN is a rare disease where disease progression causes increasing patient burden, underscoring the need for therapies that prevent kidney function decline and HRQoL deterioration while reducing mortality.
format Online
Article
Text
id pubmed-8410133
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Columbia Data Analytics, LLC
record_format MEDLINE/PubMed
spelling pubmed-84101332021-10-22 A Systematic Literature Review of the Epidemiology, Health-Related Quality of Life Impact, and Economic Burden of Immunoglobulin A Nephropathy Kwon, Christina Soeun Daniele, Patrick Forsythe, Anna Ngai, Christopher J Health Econ Outcomes Res Nephrologic/Hepatologic Conditions Introduction: This systematic literature review analyzed published evidence on IgA nephropathy (IgAN), focusing on US epidemiology, health-related quality of life (HRQoL), and economic burden of illness. Methods: Using Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, Embase®, MEDLINE®, Cochrane, and Econlit (January 2010 to June 2020) were searched, along with relevant congresses (2017-2020). Results: Of 123 epidemiologic studies selected for data extraction, 24 reported IgAN diagnosis rates ranging from 6.3% to 29.7% among adult and pediatric patients undergoing renal biopsy, with all reported US rates <15%. No US studies reported IgAN prevalence. A meta-analysis of US studies calculated an annual incidence of 1.29/100 000 people, translating to an annual US incidence of 4236 adults and children. Relative to Europe, the United States had more patients diagnosed with IgAN in later chronic kidney disease stages. US rates of transition to end-stage renal disease (ESRD) ranged from 12.5% to 23% during 3-3.9 years of observation, rising to 53% during 19 years of observation. Across 8 studies reporting HRQoL, pain and fatigue were the most reported symptoms, and patients consistently ranked kidney function and mortality as the most important treatment outcomes. Patients with glomerulopathy reported worse mental health than healthy controls or hemodialysis patients; proteinuria was significantly associated with poorer HRQoL and depression. Conclusion: While economic evidence in IgAN remains sparse, management of ESRD is a major cost driver. IgAN is a rare disease where disease progression causes increasing patient burden, underscoring the need for therapies that prevent kidney function decline and HRQoL deterioration while reducing mortality. Columbia Data Analytics, LLC 2021-09-01 /pmc/articles/PMC8410133/ /pubmed/34692885 http://dx.doi.org/10.36469/001c.26129 Text en https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (4.0) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Nephrologic/Hepatologic Conditions
Kwon, Christina Soeun
Daniele, Patrick
Forsythe, Anna
Ngai, Christopher
A Systematic Literature Review of the Epidemiology, Health-Related Quality of Life Impact, and Economic Burden of Immunoglobulin A Nephropathy
title A Systematic Literature Review of the Epidemiology, Health-Related Quality of Life Impact, and Economic Burden of Immunoglobulin A Nephropathy
title_full A Systematic Literature Review of the Epidemiology, Health-Related Quality of Life Impact, and Economic Burden of Immunoglobulin A Nephropathy
title_fullStr A Systematic Literature Review of the Epidemiology, Health-Related Quality of Life Impact, and Economic Burden of Immunoglobulin A Nephropathy
title_full_unstemmed A Systematic Literature Review of the Epidemiology, Health-Related Quality of Life Impact, and Economic Burden of Immunoglobulin A Nephropathy
title_short A Systematic Literature Review of the Epidemiology, Health-Related Quality of Life Impact, and Economic Burden of Immunoglobulin A Nephropathy
title_sort systematic literature review of the epidemiology, health-related quality of life impact, and economic burden of immunoglobulin a nephropathy
topic Nephrologic/Hepatologic Conditions
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8410133/
https://www.ncbi.nlm.nih.gov/pubmed/34692885
http://dx.doi.org/10.36469/001c.26129
work_keys_str_mv AT kwonchristinasoeun asystematicliteraturereviewoftheepidemiologyhealthrelatedqualityoflifeimpactandeconomicburdenofimmunoglobulinanephropathy
AT danielepatrick asystematicliteraturereviewoftheepidemiologyhealthrelatedqualityoflifeimpactandeconomicburdenofimmunoglobulinanephropathy
AT forsytheanna asystematicliteraturereviewoftheepidemiologyhealthrelatedqualityoflifeimpactandeconomicburdenofimmunoglobulinanephropathy
AT ngaichristopher asystematicliteraturereviewoftheepidemiologyhealthrelatedqualityoflifeimpactandeconomicburdenofimmunoglobulinanephropathy
AT kwonchristinasoeun systematicliteraturereviewoftheepidemiologyhealthrelatedqualityoflifeimpactandeconomicburdenofimmunoglobulinanephropathy
AT danielepatrick systematicliteraturereviewoftheepidemiologyhealthrelatedqualityoflifeimpactandeconomicburdenofimmunoglobulinanephropathy
AT forsytheanna systematicliteraturereviewoftheepidemiologyhealthrelatedqualityoflifeimpactandeconomicburdenofimmunoglobulinanephropathy
AT ngaichristopher systematicliteraturereviewoftheepidemiologyhealthrelatedqualityoflifeimpactandeconomicburdenofimmunoglobulinanephropathy